Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Risk of colorectal cancer after initiation of orlistat: matched cohort study.

Hong JL, Meier CR, Sandler RS, Jick SS, Stürmer T.

BMJ. 2013 Aug 27;347:f5039. doi: 10.1136/bmj.f5039.

PMID:
23982291
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
[PubMed - indexed for MEDLINE]
3.

Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink.

Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L.

BMJ. 2013 Apr 12;346:f1936. doi: 10.1136/bmj.f1936.

PMID:
23585064
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Safety profile of orlistat: results of a prescription-event monitoring study.

Acharya NV, Wilton LV, Shakir SA.

Int J Obes (Lond). 2006 Nov;30(11):1645-52. Epub 2006 Mar 21.

PMID:
16552401
[PubMed - indexed for MEDLINE]
5.

Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.

Czernichow S, Knol MJ, Fezeu L, Grobbee DE.

Eur J Prev Cardiol. 2012 Jun;19(3):484-9. doi: 10.1177/1741826711406058. Epub 2011 Apr 4.

PMID:
21464100
[PubMed - indexed for MEDLINE]
6.

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

Perrio MJ, Wilton LV, Shakir SA.

Obesity (Silver Spring). 2007 Nov;15(11):2712-22.

PMID:
18070762
[PubMed - indexed for MEDLINE]
7.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.

O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

Health Technol Assess. 2001;5(18):1-81. Review.

PMID:
11399238
[PubMed - indexed for MEDLINE]
Free Article
8.

Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.

Bloch KV, Salles GF, Muxfeldt ES, Da Rocha Nogueira A.

J Hypertens. 2003 Nov;21(11):2159-65.

PMID:
14597860
[PubMed - indexed for MEDLINE]
9.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
[PubMed - indexed for MEDLINE]
10.

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.

PMID:
20594533
[PubMed - indexed for MEDLINE]
Free Article
11.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
[PubMed - indexed for MEDLINE]
12.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
[PubMed - indexed for MEDLINE]
13.

[Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat].

Vray M, Joubert JM, Eschwège E, Liard F, Fagnani F, Montestruc F, Fages S, Bégaud B.

Therapie. 2005 Jan-Feb;60(1):17-24. French.

PMID:
15929469
[PubMed - indexed for MEDLINE]
14.
15.

Orlistat: a second look. At best, a minor adjunct to dietary measures.

[No authors listed]

Prescrire Int. 2002 Feb;11(57):10-2.

PMID:
11985367
[PubMed - indexed for MEDLINE]
16.

Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.

Tyczynski JE, Oleske DM, Klingman D, Ferrufino CP, Lee WC.

Drug Saf. 2012 Aug 1;35(8):629-44. doi: 10.2165/11599220-000000000-00000.

PMID:
22788234
[PubMed - indexed for MEDLINE]
17.

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M.

Lancet. 1998 Jul 18;352(9123):167-72.

PMID:
9683204
[PubMed - indexed for MEDLINE]
18.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
[PubMed - indexed for MEDLINE]
19.

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension.

Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I; orlistat and resistant hypertension investigators.

J Hypertens. 2002 Nov;20(11):2257-67.

PMID:
12409965
[PubMed - indexed for MEDLINE]
20.

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.

Obes Res. 2000 Jan;8(1):49-61.

PMID:
10678259
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk